Hong Kong is solidifying its role as a leading biotech fundraising and commercialization hub, with significant funding and IPO activity observed recently. At a recent event at Hong Kong Science Park, over 100 biotech professionals gathered to showcase advances in clinical trials and fundraising efforts. Notably, oncology start-up Inxmed raised over US$130 million and plans to list in Hong Kong, benefiting from the local infrastructure for patient recruitment and regulatory support. Other firms, such as Health Hope Pharma and Arthrosi Therapeutics, reported significant licensing agreements and funding, highlighting a thriving biotech ecosystem in the region. HKSTP’s initiatives, including business matchmaking, aim to connect companies with investors to further drive progress in the sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.thestandard.com.hk/innovation/article/328056/HKSTP-biotech-pipeline-moves-towards-listings-amid-strong-deal-flow
